Condition: Obesity or Overweight · Sponsor: Amgen
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Cahaba Research, Inc. | Pelham, Alabama, United States | Recruiting |
| Arizona Clinical Trials | Chandler, Arizona, United States | Recruiting |
| Epic Medical Research - Sun City | Sun City, Arizona, United States | Recruiting |
| Desert Oasis Healthcare Medical Group | Palm Springs, California, United States | Recruiting |
| Inland Empire Liver Foundation | Rialto, California, United States | Recruiting |
| Peninsula Research Associates | Rolling Hills Estates, California, United States | Recruiting |
| Apex Clinical Research | San Diego, California, United States | Recruiting |
| Southern California Clinical Research | Santa Ana, California, United States | Recruiting |
| University of Florida Department of Medicine | Gainesville, Florida, United States | Recruiting |
| Aga Clinical Trials | Hialeah, Florida, United States | Recruiting |
| South Florida Clinical Research | Margate, Florida, United States | Recruiting |
| New Horizon Research Center | Miami, Florida, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07575399